Literature DB >> 17107989

Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension.

F Perros1, P Dorfmüller, R Souza, I Durand-Gasselin, S Mussot, M Mazmanian, P Hervé, D Emilie, G Simonneau, M Humbert.   

Abstract

In the present study, the hypothesis that dendritic cells (DCs), key players in immunity and tolerance, might be involved in the immunopathology of idiopathic pulmonary arterial hypertension (IPAH) was tested. The phenotype and localisation of DCs were characterised by immunohistochemistry and double-labelling immunofluorescence in lung samples from controls, human IPAH patients and an experimental pulmonary hypertension model (monocrotaline-exposed rats). As compared with controls, morphometric analysis demonstrated increased numbers of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin (DC-SIGN)-positive cells in muscular pulmonary arteries in IPAH and OX-62-positive DCs in monocrotaline-induced pulmonary hypertension. In human samples, the mean+/-SEM number of DC-SIGN-positive cells.artery(-1) of 100-300 microm diameter was 1.4+/-0.4 in controls versus 26.4+/-2.7 in IPAH. In rats, the number of OX-62-positive cells.artery(-1) of 50-150 microm diameter was 0.5+/-0.2 in controls, and 0.7+/-0.5, 3.1+/-0.5 and 8.4+/-0.6 at day 7, 14 and 28 after monocrotaline exposure, respectively. Human complex lesions of muscular pulmonary arteries showed transmural DC infiltration. Phenotyping revealed an immature DC profile in human and experimental pulmonary hypertension. The results support the concept that immature dendritic cells accumulate in remodelled pulmonary vessels and hence could be involved in the immunopathology of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107989     DOI: 10.1183/09031936.00094706

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  62 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 2.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies.

Authors:  Kelley L Colvin; Patrick J Cripe; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

4.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  The cancer paradigm of severe pulmonary arterial hypertension.

Authors:  Pradeep R Rai; Carlyne D Cool; Judy A C King; Troy Stevens; Nana Burns; Robert A Winn; Michael Kasper; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

7.  T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension.

Authors:  E D Austin; M T Rock; C A Mosse; C L Vnencak-Jones; S M Yoder; I M Robbins; J E Loyd; B O Meyrick
Journal:  Respir Med       Date:  2009-10-31       Impact factor: 3.415

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

10.  The lung vascular filter as a site of immune induction for T cell responses to large embolic antigen.

Authors:  Monique A M Willart; Hendrik Jan de Heer; Hamida Hammad; Thomas Soullié; Kim Deswarte; Björn E Clausen; Louis Boon; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.